Items Tagged ‘kyprolis’

March 22nd, 2017

Kyprolis® Significantly Improves Overall Survival Compared To Velcade® In Relapsed Or Refractory Multiple Myeloma

By

The ENDEAVOR trial results were updated at the 16th International Myeloma Workshop in New Delhi.  The trial demonstrated that Kyprolis (Carfilzomib) not only significantly extended progression-free survival compared to Velcade (Bortezomib), but also overall improved overall survival, making it a clinically meaningful advance in the treatment of relapsed or refractory multiple myeloma.  Patients with relapsed […]

View full entry

Tags: kyprolis, Multiple Myeloma, News, proteosome inhibitors


January 26th, 2016

Combo Therapy of Kyprolis plus Dexamethasone Approved for Recurrent Multiple Myeloma

By

The United States Food and Drug Administration (FDA) recently approved a new treatment combination consisting of Kyprolis (carfilzomib) plus dexamethasone for patients with relapsed or refractory multiple myeloma. Multiple myeloma is a type of blood cancer that affects certain immune cells called plasma cells. Healthy plasma cells produce proteins called antibodies that are an important […]

View full entry

Tags: carfilzomib, dexamethasone, ENDEAVOR, fda, kyprolis, Multiple Myeloma, News, Recurrent Multiple Myeloma


April 27th, 2015

Study Demonstrates Superiority Of Kyprolis® over Velcade® in Patients With Relapsed Multiple Myeloma

By

The results from a planned interim analysis of the Phase 3 head-to-head clinical trial ENDEAVOR evaluating Kyprolis® (carfilzomib in combination with low-dose dexamethasone versus Velcade® (bortezomib) and low-dose dexamethasone have demonstrated that the Kyprolis® treated patients lived twice as long without their disease worsening. Multiple myeloma is a cancer of plasma cells, which are a […]

View full entry

Tags: bortezimib, carfilzomib, ENDEAVOR, kyprolis, Multiple Myeloma, News, velcade


December 7th, 2014

ASH 2014: Kyprolis®-Based Treatment Demonstrates Significant Advance in the Treatment of Multiple Myeloma

By

Results of the phase 3 clinical trial ASPIRE were presented at the American Society of Hematology Meetings this week. Relapsed multiple myeloma patients treated with Kyprolis® (carfilzomib) in combination with Revlimid® (lenalidomide) and low-dose dexamethasone lived significantly longer without their disease worsening compared to patients treated with Revlimid®and low-dose dexamethasone. Multiple myeloma is a cancer […]

View full entry

Tags: aspire, kyprolis, Multiple Myeloma, News, Recurrent Multiple Myeloma


August 7th, 2014

Kyprolis Improves Progression-Free Survival in Multiple Myeloma

By

Amgen announced that a planned interim analysis demonstrated that the Phase 3 clinical trial ASPIRE met its primary endpoint of progression-free survival (PFS).  Patients treated with Kyprolis® (carfilzomib) in combination with Revlimid® (lenalidomide) and low-dose dexamethasone lived significantly longer without their disease worsening compared to patients treated with Revlimid and low-dose dexamethasone. Multiple myeloma is […]

View full entry

Tags: carfilzomib, Info Type, kyprolis, Multiple Myeloma, News, Recurrent Multiple Myeloma